Full text
5/2026
vol. 43
Letter to the Editor
To kill two birds with one stone: a case report on the use of dupilumab in eczematous eruption and managing anti- PD-1 adverse effects in a melanoma patient
The Doctoral School, University of Rzeszow, Poland
Chair and Department of Dermatology, Medical University of Silesia, Katowice, Poland
Doctoral School, Medical University of Silesia, Katowice, Poland
Adv Dermatol Allergol 2026; XLIII (5): 584-587
Data publikacji online: 2026/10/23
- Kuo AM, Gu S, Stoll J, et al. Management of immune-related cutaneous adverse events with dupilumab. J Immunother Cancer 2023; 11: e007324.
- Fournier C, Hirsch I, Spreafico A, et al. Dupilumab as a treatment for cutaneous immune-related adverse events induced by immune checkpoint inhibitors: a case series and review of the literature. SAGE Open Med Case Rep 2023; 11: 2050313X231195462.
- Zhang Z, Li S, Wang Y, et al. A real-world observational study of dupilumab treatment in adult patients with prurigo nodularis. An Bras Dermatol 2023; 98: 440-8.
- Lacouture ME, Goleva E, Shah N, et al. Immunologic profiling of immune-related cutaneous adverse events with checkpoint inhibitors reveals polarized actionable pathways. Clin Cancer Res 2024; 30: 2822-34.
- Panou E, Stavridi F, Nikolaou C, et al. Dupilumab for the treatment of immune checkpoint blockers’ induced pruritus. J Eur Acad Dermatol Venereol 2023; 37: e1475-6.
- Martínez BQ, Domínguez Cherit JG, Rosales Sotomayor Á, et al. Disseminated nummular eczema following nivolumab treatment: successful management with dupilumab. JEADV Clin Pract 2024; 3: 1720-2.
- Apalla Z, Nikolaou V, Fattore D, et al. European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events. The EADV task force ‘Dermatology for cancer patients’ position statement. J Eur Acad Dermatol Venereol 2022; 36: 332-50.
- Mima Y, Ohtsuka T, Ebato I, et al. Review of T helper 2-type inflammatory diseases following immune checkpoint inhibitor treatment. Biomedicines 2024; 12: 1886.
- Yosipovitch G, Kim BS, Kwatra SG, et al. Dupilumab improves pruritus and skin lesions in patients with prurigo nodularis: pooled results from 2 phase 3 trials (LIBERTY-PN PRIME and PRIME2). JAAD Int 2024; 16: 163-74.
- Pereira MP, Steinke S, Zeidler C, et al. European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo. J Eur Acad Dermatol Venereol 2018; 32: 1059-65.
Copyright: © 2026 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
